Q1 2021 13F Holders as of 3/31/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
54.7M
-
Number of holders
-
86
-
Total 13F shares, excl. options
-
31M
-
Shares change
-
+1.06M
-
Total reported value, excl. options
-
$480M
-
Value change
-
+$23.8M
-
Put/Call ratio
-
3.54
-
Number of buys
-
58
-
Number of sells
-
-26
-
Price
-
$15.48
Significant Holders of Marinus Pharmaceuticals, Inc. - Common Stock (MRNS) as of Q1 2021
107 filings reported holding MRNS - Marinus Pharmaceuticals, Inc. - Common Stock as of Q1 2021.
Marinus Pharmaceuticals, Inc. - Common Stock (MRNS) has 86 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31M shares
of 54.7M outstanding shares and own 56.69% of the company stock.
Largest 10 shareholders include Lion Point Capital, LP (3.62M shares), Avoro Capital Advisors LLC (3.24M shares), BlackRock Inc. (2.73M shares), VR Adviser, LLC (2.64M shares), BOXER CAPITAL, LLC (2.4M shares), 683 Capital Management, LLC (1.89M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (1.83M shares), VANGUARD GROUP INC (1.7M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.46M shares), and Bain Capital Life Sciences Investors, LLC (1.43M shares).
This table shows the top 86 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.